Obesity Medicine最新文献

Prevalence of thyroid disorders in patients with diabetes and hypertension in India: A systematic review and meta-analysis

Obesity Medicine Pub Date : 2025-04-01 DOI: 10.1016/j.obmed.2025.100609

Bhavya Sharma, Vaibhav Chaudhary, Sweta Kumari, Biplab Pal

{"title":"Prevalence of thyroid disorders in patients with diabetes and hypertension in India: A systematic review and meta-analysis","authors":"Bhavya Sharma, Vaibhav Chaudhary, Sweta Kumari, Biplab Pal","doi":"10.1016/j.obmed.2025.100609","DOIUrl":"10.1016/j.obmed.2025.100609","url":null,"abstract":"<div><h3>Background and aims</h3><div>Thyroid disorders are common in people with hypertension and diabetes. Given the rising spread of these conditions in India, this study determined the prevalence of thyroid disorders in Indian patients with hypertension and diabetes.</div></div><div><h3>Methods</h3><div>Literature search was done for studies published between 2000 and August 2024, reporting thyroid disorder prevalence in Indian patients with hypertension and diabetes. Analysis was conducted using RStudio, with subgroup analysis by region. Quality assessment was performed using Joanna Briggs Institute checklist. Heterogeneity and publication bias were appraised.</div></div><div><h3>Results</h3><div>The pooled prevalence of thyroid disorders was 16.1 % (95 % CI: 1.8–67.2, I<sup>2</sup> = 100 %, <em>p</em> < 0.01) in hypertensive patients and 23.8 % (95 % CI: 20.5–27.5, I<sup>2</sup> = 95 %, <em>p</em> < 0.01) in diabetic patients. Subclinical hypothyroidism (47.5 %) was the most common thyroid disorder in diabetic patients, followed by hypothyroidism (39.7 %). Among diabetic patients, prevalence was 32.6 % in Eastern, 25.2 % in Northern, 24.5 % in Western, and 19.5 % in Southern region, with no significant differences (<em>p</em> = 0.12).</div></div><div><h3>Conclusion</h3><div>Thyroid disorders are common in patients with hypertension and diabetes. Routine screening and integrating thyroid monitoring into diabetes and hypertension care can improve outcomes. More research is needed to standardize diagnostic methods and identify risk factors.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100609"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive overview of polycystic ovary syndrome: Pathophysiology, clinical features, and emerging therapeutic approaches

Obesity Medicine Pub Date : 2025-03-28 DOI: 10.1016/j.obmed.2025.100606

Larsa Naji Adam, Lina N. Adam

{"title":"Comprehensive overview of polycystic ovary syndrome: Pathophysiology, clinical features, and emerging therapeutic approaches","authors":"Larsa Naji Adam, Lina N. Adam","doi":"10.1016/j.obmed.2025.100606","DOIUrl":"10.1016/j.obmed.2025.100606","url":null,"abstract":"<div><div>Polycystic Ovary Syndrome (PCOS) is the leading cause of anovulatory infertility, affecting 90–95 % of women seeking fertility treatment. It is characterized by hormonal imbalances, such as elevated luteinizing hormone, androgens, and insulin, along with reduced follicle-stimulating hormone (FSH). These imbalances result in clinical features like oligomenorrhea, amenorrhea, and polycystic ovaries, and often lead to complications such as infertility, metabolic disorders, and increased cardiovascular risk. Epidemiological studies show significant regional and age-related variations in the prevalence of PCOS, highlighting the need for further research into its causes and future impact. The pathophysiology of PCOS is complex, involving genetic, endocrine, environmental, and lifestyle factors. Genetic contributors include mutations in the AR, FTO, and FSHR genes, while hyperandrogenism and insulin resistance are key endocrine disruptions. Environmental and lifestyle factors, such as diet, obesity, and exposure to endocrine-disrupting chemicals, also worsen symptoms. Clinically, PCOS presents with a range of symptoms, including menstrual irregularities, hirsutism, infertility, obesity, and associated metabolic and cardiovascular risks. The condition also significantly affects mental health and quality of life. Emerging therapies, including personalized medicine and complementary approaches, offer promise for more effective, individualized treatments. This review provides an overview of PCOS, its pathophysiology, clinical manifestations, diagnostic criteria, and management options, with the aim of informing clinical practice and guiding future research.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100606"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143734730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protein phosphatase 6 as an important downstream target of fibroblast growth 21 and its therapeutic analogues in attenuating MASH development

Obesity Medicine Pub Date : 2025-03-24 DOI: 10.1016/j.obmed.2025.100602

Jia Nuo Feng , Qingchun Tong , Tianru Jin

引用次数: 0

Clinical evaluation of safety and efficacy of biozen syrup in patients with hyperlipidemia

Obesity Medicine Pub Date : 2025-03-21 DOI: 10.1016/j.obmed.2025.100601

Rajappan Chandra Satish Kumar , Subramaniam Nandhini , Bhuvaneshwaran Mothishwaran , Chittaranjan Das , Anavarathan Vallipuram , Muhasaparur Ganesan Rajanandh

{"title":"Clinical evaluation of safety and efficacy of biozen syrup in patients with hyperlipidemia","authors":"Rajappan Chandra Satish Kumar , Subramaniam Nandhini , Bhuvaneshwaran Mothishwaran , Chittaranjan Das , Anavarathan Vallipuram , Muhasaparur Ganesan Rajanandh","doi":"10.1016/j.obmed.2025.100601","DOIUrl":"10.1016/j.obmed.2025.100601","url":null,"abstract":"<div><h3>Background</h3><div>The increasing prevalence of hyperlipidemia has become one of the greatest threats to public health. While pharmacological treatments are effective for the management of hyperlipidemia, alternative approaches like dietary supplements are gaining interest for their natural benefits. The present study aimed to evaluate the safety and efficacy of biozen syrup comprised of garlic, apple-cider vinegar, lemon and honey for controlling patients with hyperlipidemia.</div></div><div><h3>Methods</h3><div>A prospective, open-label study was conducted on patients who had hyperlipidemia. Patients were given with biozen syrup (15 ml in 100 ml warm water) twice daily for 90 days. Clinical assessments and laboratory findings were compared before (day 0) and after (day 90) starting the treatment.</div></div><div><h3>Results</h3><div>A total of 60 patients were enrolled in the study. After administration of biozen syrup, serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), high-sensitivity C-reactive protein (hs-CRP), homocysteine, and apolipoprotein B levels significantly decreased (<em>p</em> < 0.001). The mean serum apolipoprotein A1, high-density lipoprotein cholesterol (HDL-C) were raised post-treatment (<em>p</em> < 0.001). Treatment with biozen syrup had no significant effects (<em>p</em> > 0.001) on serum biochemical parameters related to liver, kidney functions and hematological parameters. Gastrointestinal disturbances was the most frequently occurred ADR (58 %).</div></div><div><h3>Conclusion</h3><div>The results demonstrated that the biozen was safe and efficacious in lowering the levels of bad cholesterol and raising the levels of good cholesterol.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100601"},"PeriodicalIF":0.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143738016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of 52-week liraglutide treatment on diabetes risk and glycaemic control in women with obesity and prior gestational diabetes. A randomized, double-blind, placebo-controlled study

Obesity Medicine Pub Date : 2025-03-01 DOI: 10.1016/j.obmed.2025.100596

Roosa Perämäki , Meri-Maija Ollila , Janne Hukkanen , Marja Vääräsmäki , Jukka Uotila , Saara Metso , Heidi Hakkarainen , Reeta Rintamäki , Eliisa Löyttyniemi , Heidi Immonen , Risto Kaaja

{"title":"Effect of 52-week liraglutide treatment on diabetes risk and glycaemic control in women with obesity and prior gestational diabetes. A randomized, double-blind, placebo-controlled study","authors":"Roosa Perämäki , Meri-Maija Ollila , Janne Hukkanen , Marja Vääräsmäki , Jukka Uotila , Saara Metso , Heidi Hakkarainen , Reeta Rintamäki , Eliisa Löyttyniemi , Heidi Immonen , Risto Kaaja","doi":"10.1016/j.obmed.2025.100596","DOIUrl":"10.1016/j.obmed.2025.100596","url":null,"abstract":"<div><h3>Aims</h3><div>We investigated the effect of 52-week liraglutide treatment on the incidence of type 2 diabetes (T2D) compared with placebo treatment in women with obesity and previous gestational diabetes (pGDM) requiring medical treatment. As secondary outcomes, the prevalence of prediabetes and glycaemic control were investigated.</div></div><div><h3>Methods</h3><div>Women were randomized to once daily subcutaneous liraglutide 1.8 mg or placebo for 52 weeks. Oral glucose tolerance test, C-peptide, insulin, HbA1c and lipids were determined at baseline, 26 weeks, and 52 weeks.</div></div><div><h3>Results</h3><div>In total, 75 women [mean age of 34.5 years, median BMI of 38.0 kg/m<sup>2</sup>] were assigned to liraglutide (n = 37) or placebo (n = 38). At 52 weeks, T2D was diagnosed in 3% (n = 1) of the liraglutide group and 8% (n = 2) of the placebo group (p = 0.58), and prediabetes in 27% (n = 9) and 58% (n = 15), respectively (p = 0.032). In intention-to-treat analysis, 52-week liraglutide treatment reduced fasting glucose [group × time interaction p = 0.0047; estimated treatment difference (ETD) at 52 weeks −0.5 mmol/L, p = 0.0020], HbA1c [p = 0.020; ETD -0.2% (−2.1 mmol/mol), p = 0.056], weight (p = 0.0087; ETD -6.2 kg, p = 0.20) and waist circumference (p = 0.022; ETD -3.9 cm, p = 0.25), and improved Matsuda index (p = 0.049; ETD 0.7, p = 0.011) compared with placebo.</div></div><div><h3>Conclusions</h3><div>Liraglutide reduces the prevalence of prediabetes and improves glycaemic control in women with obesity and pGDM. Due to few T2D cases, the effect of liraglutide on diabetes risk could not be reliably assessed.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100596"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143520700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Survey on the herbal combinations in traditional Vietnamese medicine formulas for obesity treatment based on literature

Obesity Medicine Pub Date : 2025-03-01 DOI: 10.1016/j.obmed.2025.100598

Duong Thi Huong Nguyen, Huy Khanh Tang, An Thi Hoai Nguyen, Luu Bao Le

{"title":"Survey on the herbal combinations in traditional Vietnamese medicine formulas for obesity treatment based on literature","authors":"Duong Thi Huong Nguyen, Huy Khanh Tang, An Thi Hoai Nguyen, Luu Bao Le","doi":"10.1016/j.obmed.2025.100598","DOIUrl":"10.1016/j.obmed.2025.100598","url":null,"abstract":"<div><h3>Objectives</h3><div>Today, obesity is a significant public health concern. Traditional medicine, known for its minimal side effects and positive outcomes, is increasingly being utilized as an alternative intervention in clinical practice. This study seeks to examine Vietnamese literature to identify herbs that can aid in reducing obesity and to interpret the association rules among these herbs.</div></div><div><h3>Methods</h3><div>Four hundred thirty-six formulas were collected from 43 documents suited to inclusion criteria. Using Microsoft Excel 2016, we continuously interpreted the characteristics of 320 herbs extracted from 436 anti-obesity formulas. The Apriori algorithm, operated by R Studio version 4.3.3, investigated the association rules among core materials.</div></div><div><h3>Results</h3><div>Shan Zha (<em>Fructus crataegi</em>) is the most popular herb mentioned in 436 compounded medications. The predominant property and flavor were warm (33,02%) and sweet (52,7%), respectively. Eventually, we also found 18 association rules and screened out 7 potential anti-obesity herbs. Each rule consists of two or three components. Especially, the greatest prevalent associated law is a triple combination among Fu Ling (<em>Poria cocos</em>)<em>,</em> Ban Xia (<em>Rhizoma pinelliae</em>)<em>,</em> and Chen Pi (<em>Pericarpium citri reticulatae</em>).</div></div><div><h3>Conclusions</h3><div>This study documents traditional Vietnamese medicinal knowledge on herbs with anti-obesity properties. According to the traditional function, all of herbs can be divided into these classifications: Tonify Spleen-Qi, Move Qi and invigorate Blood, Resolve retention of food, Resolve Dampness and Promoting diuresis. Besides, the pharmacological functions of them are suppressing appetite, inhibition of fat absorption and elevation of fat metabolism rate.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100598"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The application of biohacking in obesity medicine: New perspectives on obesity's socioeconomic effects and disease mechanisms 生物黑客技术在肥胖症医学中的应用：肥胖症的社会经济影响和疾病机制新视角

Obesity Medicine Pub Date : 2025-03-01 DOI: 10.1016/j.obmed.2025.100586

Ammar Abdulrahman Jairoun

{"title":"The application of biohacking in obesity medicine: New perspectives on obesity's socioeconomic effects and disease mechanisms","authors":"Ammar Abdulrahman Jairoun","doi":"10.1016/j.obmed.2025.100586","DOIUrl":"10.1016/j.obmed.2025.100586","url":null,"abstract":"<div><div>Obesity is a complex health issue that affects every nation worldwide. It is associated with various economic and societal difficulties, substantial comorbidities, and complex disease mechanisms. Conventional approaches to treating obesity often do not result in tailored, sustainable health outcomes. However, new approaches to its treatment may be found in biohacking, an approach defined by the combined use of technology, advances in science, and self-experimentation. This Editorial explores biohacking's potential role in managing obesity, particularly in addressing its behavioral factors, socioeconomic effects, and disease mechanisms. Biohacking aims to manipulate core biological processes such as gene expression, systemic inflammation, and cellular health to reduce the risks associated with obesity and enhance metabolic health. These techniques include nutrigenomics, microbiome manipulation, and intermittent fasting with wearable technologies and ongoing glucose monitors, allowing people to access their health data in real time and personalize their approach to managing their weight. With the support of habit-establishing strategies and mindfulness tools, behavioral interventions underpinned by biohacking principles can deliver long-term changes to people's lifestyles. Biohacking offers potential benefits not only for the individual but also for society, where it may lessen healthcare inequalities by providing low-cost, accessible tools. Nonetheless, ethical concerns about self-experimentation and biohacking's equitability and safety remain. However, integrating biohacking into conventional medicine could transform obesity management and tackle its many associated factors by delivering tailored, preventative treatment options.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100586"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143628460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypertension in obese and severely malnourished children in resource-limited countries: Preliminary results of a comparative cross-sectional study

Obesity Medicine Pub Date : 2025-03-01 DOI: 10.1016/j.obmed.2025.100594

Mudahama Francis Neema , Mongwa Justin Mbikilile , Archippe Muhandule Birindwa

{"title":"Hypertension in obese and severely malnourished children in resource-limited countries: Preliminary results of a comparative cross-sectional study","authors":"Mudahama Francis Neema , Mongwa Justin Mbikilile , Archippe Muhandule Birindwa","doi":"10.1016/j.obmed.2025.100594","DOIUrl":"10.1016/j.obmed.2025.100594","url":null,"abstract":"<div><h3>Backgroung</h3><div>Hypertension is one of the world's leading causes of death, and few studies have shown the impact of its frequency on malnourished and overweight children.</div></div><div><h3>Objective</h3><div>the objective of this study is to describe the frequency of hypertension in obese and malnourished children comparing two areas, urban and rural in the country with limited resources, preliminary results of the cross-sectional study.</div></div><div><h3>Method</h3><div>In this study, we describe the preliminary results of the cross-sectional study we conducted, including obese, malnourished children from selected rural and urban health centers dealing with eating disorders and nutrition in the eastern Democratic Republic of Congo (DRC).</div></div><div><h3>Results</h3><div>The frequency of arterial hypertension in obese, malnourished children of normal constitution was 37.8% in two zones, rural and urban, and the most represented age was over 10 years.</div></div><div><h3>Conclusion</h3><div>Hypertension in children is still an under-diagnosed condition, yet its frequency remains high, and even obese and malnourished children are not excluded. If primary health care facilities were equipped with the appropriate measures, early diagnosis would be possible.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100594"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Healing wounds in diabetes: Exploring cutting-edge natural extracellular vesicle therapeutics

Obesity Medicine Pub Date : 2025-02-21 DOI: 10.1016/j.obmed.2025.100597

Mumtaj Bano Miya , Pankaj Chaturvedi , Vandana Pathak , Prakash Chandra Gupta , Anuradha Kalani

引用次数: 0

Association and inequality between socioeconomic status and the prevalence of overweight and obesity among adults aged 18 and older in Bangladesh

Obesity Medicine Pub Date : 2025-02-19 DOI: 10.1016/j.obmed.2025.100595

Sukanta Das

{"title":"Association and inequality between socioeconomic status and the prevalence of overweight and obesity among adults aged 18 and older in Bangladesh","authors":"Sukanta Das","doi":"10.1016/j.obmed.2025.100595","DOIUrl":"10.1016/j.obmed.2025.100595","url":null,"abstract":"<div><h3>Background</h3><div>Overweight and obesity have emerged as significant public health concerns in Bangladesh. This study aims to assess the association between socioeconomic status (SES) and the prevalence of overweight and obesity while identifying socioeconomic inequalities among adults aged 18 and older in Bangladesh.</div></div><div><h3>Methods</h3><div>Using data from the Bangladesh Demographic and Health Survey (BDHS) 2017–18, this study analyzed a sample of 24,478 adults. Overweight and obesity were classified according to the World Health Organization's Body Mass Index (BMI) guidelines. SES was measured by wealth index, and its association with overweight and obesity was examined using multivariate logistic regression analysis. Socioeconomic inequality was evaluated using concentration curves and indexes.</div></div><div><h3>Results</h3><div>The overall prevalence of overweight and obesity was 31.8% and 13.4%, respectively. Even after controlling for age, gender, education, and place of residence, higher socioeconomic status was significantly associated with an increased risk of being overweight or obese. Adults in the richest wealth category were 3.2 times more likely to be overweight and 9.8 times more likely to be obese compared to those in the poorest category (p < 0.01). The concentration index of 0.35 (CI: 0.33 to 0.37; <span><math><mrow><mi>p</mi></mrow></math></span> < 0.01) indicated that overweight and obesity were more prevalent among wealthier adults, highlighting a pro-rich inequality.</div></div><div><h3>Conclusion</h3><div>There is a significant socioeconomic disparity in the prevalence of overweight and obesity in Bangladesh, with wealthier adults disproportionately affected. Targeted public health initiatives are needed to curb this growing epidemic, particularly among wealthier groups, to reduce obesity-related non-communicable diseases.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100595"},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143465126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0